skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration


Exact Sciences Corp. is acquiring Genomic Health Inc. in a mammoth $2.8bn deal combining two of the world's leading cancer diagnostics firms.

Under the terms of the agreement, Exact Sciences will pay $72 per share in a cash and stock transaction expected to close by the end of 2019. 

The deal diversifies Exact Sciences' range of products to include breast and prostate cancer and adds Genomic Health's extensive commercial sales force in oncology.  Since launching in 2014, sales of Exact Sciences’ colorectal cancer diagnosis test, Cologuard have grown rapidly. In the second quarter of 2019, revenue grew 94% year-over-year. In a statement, Exact said Cologuard had captured less than 6% of the large addressable market of people over 50 years old and is aiming to grab 40% of the market share over the long-term. The combined company will have a commercial presence in more than 90 countries.

Genomic Health's strongest asset is its Oncotype IQ tests which provide personalized treatment decisions for cancer patients. The portfolio delivered more than 19% year-over-year overall revenue growth in the second quarter of 2019. In a statement, the companies said the combined commercial organization will generate revenue of approximately $1.6bn and gross profit of approximately $1.2bn in 2020. 

"Uniting the best minds and molecular diagnostics capabilities will advance the fight against cancer. Combining industry pioneers Exact Sciences and Genomic Health is a pivotal step toward building the leading cancer diagnostics company in the world," said Kevin Conroy, CEO of Exact Sciences. "Exact Sciences is continuing to grow sales and expand adoption of Cologuard at a rapid pace, and Genomic Health's Oncotype DX is the global standard of care to inform treatment decisions for women with breast cancer. Together, with our collective resources and broader platform, we will be able to provide our existing tests to more people, while also accelerating the development and launch of future cancer diagnostic tests."

The news comes on the heels of Exact Sciences' second quarter financial results, with the company reporting revenue up 94.3% to $199m. The increase was driven by Exact adding 13,000 first-time-ordering physicians during the quarter, bringing the number of US providers adopting Cologuard to about 174,000. Following the results, Exact raised its full year revenue guidance to between $800m to $810m for 2019, up from the $725m to $740m previously estimated.

Read also


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: